The company is also advancing the commercialization of Tollovid and Tollovid Daily, its oral antiviral 3CL protease inhibiting dietary supplements now.
Sponsored Content Release
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.Fina
Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer
FinancialBuzz.com News Commentary
NEW YORK, April 9, 2021 /PRNewswire/ The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in the United States in 2020. Overall, lung and bronchus cancer is the second most common cancer diagnosis with an estimated 228,820 new cases. Prostate cancer is the leading cancer diagnosis among men and the third most common diagnosis overall with 191,930 expected cases. However, the increase in competition and continuous technological advancements has led to improvements in the product portfolios of biotech firms in the field. Therefore, product approvals and product development are one of the key developmental strategies adopted by market players in the global cancer therapeutics market. And, according to a report by Mordor Intelligence, the breast c
Todos wins Notice of Allowance from European Patent Office for patent covering cancer diagnosis using TBIA Immune Profiling
CEO Gerald E Commissiong said TBIA is a game-changing approach to cancer detection as different AI-developed algorithms run for multiple cancer types on the same blood sample The TBIA method uses blood - plasma, or peripheral blood mononuclear cells - to distinguish between patients with benign tumors versus malignant tumors, in contrast to no tumors
Todos Medical Ltd (OTCQB:TOMDF), a medical diagnostics solutions company, revealed that it has received a notice of allowance from the European Patent Office covering the use of the company’s proprietary Total Biochemical Infrared Analysis (TBIA) platform to diagnose cancers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application .
Todos Medical Ltd.April 8, 2021 GMT
NEW YORK, NY, and REHOVAT, ISRAEL, April 08, 2021 (GLOBE NEWSWIRE) via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics solutions company, today announced that it has received a notice of allowance (‘Letter of Intent to Grant a Patent’) from the European Patent Office covering the use of the Company’s proprietary Total Biochemical Infrared Analysis (‘TBIA’) method that uses blood (plasma and/or peripheral blood mononuclear cells ‘PBMCs’) to distinguish between patients with benign tumors vs. malignant tumors vs. no tumors (healthy controls).